{"organizations": [], "uuid": "bc68276dc3063f60f357cab7edbe4c9728bd1c3e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.marketwatch.com", "main_image": "http://s.wsj.net/public/resources/MWimages/MW-DR328_mw_soc_NS_20150801233302.png", "site_section": "http://finance.yahoo.com/rss/headline?s=NVS", "section_title": "Yahoo! Finance: NVS News", "url": "http://www.marketwatch.com/story/xoma-enters-exclusive-license-agreement-with-novartis-2015-10-01-7914627?siteid=yhoof2", "country": "US", "title": "Xoma enters exclusive license agreement with Novartis - MarketWatch", "performance_score": 0, "site": "marketwatch.com", "participants_count": 1, "title_full": "Xoma enters exclusive license agreement with Novartis - MarketWatch", "spam_score": 0.0, "site_type": "news", "published": "2015-10-02T03:00:00.000+03:00", "replies_count": 0, "uuid": "bc68276dc3063f60f357cab7edbe4c9728bd1c3e"}, "author": "yahoo", "url": "http://www.marketwatch.com/story/xoma-enters-exclusive-license-agreement-with-novartis-2015-10-01-7914627?siteid=yhoof2", "ord_in_thread": 0, "title": "Xoma enters exclusive license agreement with Novartis - MarketWatch", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Xoma Corp. XOMA, +43.67% entered on Thursday into an exclusive license agreement with Novartis AG NVS, -0.02% to develop and commercialize its cancer-fighting antibody program. Xoma will receive an upfront payment of $37 million, could receive up to $480 million in milestone payments and is eligible to receive royalties on product sales. Novartis agreed to extend the maturity on $13.5 million of debt to September 2020. \"With this non-dilutive liquidity of essentially $50.5 million, we currently project this capital, in combination with our planned cost savings measures, will fund operations into 2017,\" said Xoma Chief Executive John Varian. \"We remain on track to begin our XOMA 358 Phase 2 clinical program this fall and fully anticipate we will have the data from these studies during that timeframe.\" Xoma's stock, currently halted for news dissemination, had plunged 80% over the past three months, while the S&P 500 SPX, +0.20% has lost 7.6%. Novartis shares edged up 0.3% in premarket trade.", "external_links": [], "published": "2015-10-02T03:00:00.000+03:00", "crawled": "2015-10-02T01:49:22.080+03:00", "highlightTitle": ""}